Combination of LErafAON with DOX or paclitaxel (PTX) led to significantly enhanced antitumor activity in all the tumor types, compared with LErafAON-alone or chemotherapeutic agent-alone treated groups, through inhibition of Raf-1 expression in tumor tissue [58] (Figure 5). The gene discussed is RAF1; the disease is neoplasm.